- Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Kronenberg, G., Berger, P., Tauber, R.F., Bandelow, B., Henkel, V., Heuser, I. Pharmacopsychiatry (2005)